Details
| Stereochemistry | MIXED |
| Molecular Formula | C23H32N2O3 |
| Molecular Weight | 384.5118 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(CN1CCN(CC(O)C(OC)C2=CC=CC=C2)CC1)C3=CC=CC=C3
InChI
InChIKey=VSTNNAYSCJQCQI-UHFFFAOYSA-N
InChI=1S/C23H32N2O3/c1-27-22(19-9-5-3-6-10-19)18-25-15-13-24(14-16-25)17-21(26)23(28-2)20-11-7-4-8-12-20/h3-12,21-23,26H,13-18H2,1-2H3
| Molecular Formula | C23H32N2O3 |
| Molecular Weight | 384.5118 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Zipeprol is disubstituted piperazine that is marketed as a non-opioid antitussive in Europe, Asia, and South America. Zipeprol is not available in the United States or Canada and has been discontinued in Europe. Zipeprol is still available in some countries in Asia and South America. Zipeprol was demonstrated to have anticough effects in animal models, to be active as a blocker of histamine and cholinergic function, to be a potent local anesthetic and to possess bronchiospasmolytic actions. it had no remarkable cardiovascular or gastrointestinal actions in the rat or dog in comparison to codeine.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:10:19 GMT 2025
by
admin
on
Mon Mar 31 18:10:19 GMT 2025
|
| Record UNII |
G5MUV8139H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
9873
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
||
|
NCI_THESAURUS |
C66917
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
||
|
WHO-VATC |
QR05DB15
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
||
|
WHO-ATC |
R05DB15
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
36910
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
DTXSID00865732
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
m11640
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL2105497
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
C013341
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
SUB00167MIG
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
DB13564
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
3212
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
34758-83-3
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
2864
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
ZIPEPROL
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
C66698
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
100000078770
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
252-191-7
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
G5MUV8139H
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | |||
|
39969
Created by
admin on Mon Mar 31 18:10:19 GMT 2025 , Edited by admin on Mon Mar 31 18:10:19 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Route of Elimination | PHARMACOKINETIC |
|
|
|||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||